HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ONCO
Onconetix, Inc.
There isn't enough reported data to score ONCO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ONCO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ONCO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ONCO PE Valuation
ONCO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ONCO Forward outlook
There aren't enough analyst estimates for ONCO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
ONCO has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus ONCO down 117%.
ONCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$766,680.00 | +$3,828,845.00 |
| Q2 2025 | -$888,080.00 | +$4,109,920.00 |
| Q1 2025 | -$1,973,700.00 | +$2,293,300.00 |
| Q4 2024 | -$2,801,175.00 | +$921,825.00 |
| Q3 2024 | -$4,595,525.00 | -$2,923,041.56 |
| Q2 2024 | -$4,998,000.00 | -$3,393,516.56 |
| Q1 2024 | -$4,267,000.00 | -$2,407,516.56 |
| Q4 2023 | -$3,723,000.00 | -$1,853,000.00 |
ONCO is still losing money, but far less than before: $766,680.00 per share over the past year, against $4,998,000.00 at its worst in mid-2024.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ONCO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ONCO on profitability, with a higher operating margin.
ONCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.1K | -84% |
| Q1 2026 | $21.5K | -79% |
| Q4 2025 | $303.6K | -57% |
| Q3 2025 | $303.7K | -25% |
| Q2 2025 | $106.5K | -85% |
| Q1 2025 | $101.6K | -75% |
ONCO's revenue has slid since its 2024 peak: $17,120 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15951% | -14134 points |
| Q1 2026 | -47657% | -35288 points |
| Q4 2025 | -422% | +3672 points |
| Q3 2025 | -681% | -31 points |
| Q2 2025 | -1817% | +114 points |
| Q1 2025 | -12369% | -9599 points |
| Q4 2024 | -4094% | N/A |
| Q3 2024 | -650% | N/A |
ONCO's operating margin was −15951% last quarter, down 14133 points from the same quarter a year ago, near the bottom of its range since 2024.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
ONCO has the stronger cash trend. Its trailing FCF is up 49% versus its history, compared with HIMS at down 84%.
ONCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$921.5K | +$3.4M |
| Q3 2024 | -$1.1M | +$1.9M |
| Q2 2024 | -$3.2M | -$1.4M |
| Q1 2024 | -$5.2M | -$788.7K |
| Q4 2023 | -$4.3M | -$1.5M |
| Q3 2023 | -$3M | -$1.2M |
| Q2 2023 | -$1.8M | +$1.4M |
| Q1 2023 | -$4.4M | -$3.6M |
ONCO has burned cash in almost every quarter: −$6M over the past year, against −$16M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ONCO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ONCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3468% | +218K shares |
| 1 year | +52301% | +224K shares |
| 3 years | +3203857% | +224K shares |
ONCO has 224,277 diluted shares, up 52301% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | $25,527 |
| Q1 2023 | $33,454 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ONCO Net Leverage
ONCO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ONCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 17.9 | Oversold |
ONCO's weekly RSI is 29 (oversold) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ONCO PE vs Healthcare Sector
ONCO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ONCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.05 | 50% below |
| 20 week MA | $7.26 | 58% below |
| 50 week MA | $229.4 | 99% below |
| 100 week MA | $3,385.0 | 100% below |
| 200 week MA | $414,179.2 | 100% below |
ONCO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ONCO on returns for 2026, with the stronger performance.
ONCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $97,580,000.0 | $1,751,000.0 | -98% |
| 2023 | $1,751,000.0 | $336,600.0 | -81% |
| 2024 | $336,600.0 | $16,365.1 | -95% |
| 2025 | $16,365.1 | $715.0 | -96% |
| 2026 YTD | $715.0 | $3.03 | -100% |
ONCO has finished every year since 2022 lower, and it's down 100% so far in 2026.